Innovative Medicine
-
Tibotec Therapeutics Becomes Janssen Therapeutics, Part Of The Janssen Pharmaceutical Companies
Unified Janssen companies around the world continue commitment to patients and to addressing unmet medical needs -
-
DACOGEN® (decitabine) showed an overall survival advantage compared with the accepted standard therapies in older patients with newly diagnosed de novo or secondary acute myeloid leukemia
Data from DACO-016 study at 2011 American Society of Clinical Oncology Annual Meeting -
Late-Breaking ASCO Data Demonstrate Circulating Tumor Cells As Potential Biomarker for Metastatic Prostate Cancer Clinical Trials
Study utilized Veridex’s CELLSEARCH® CTC Test, the only regulatory-cleared in vitro diagnostic test to capture and count CTCs -
-
Johnson & Johnson Highlights Strategies for Growth Through Differentiated Medicines, Transformational Pipeline and Global Product Launches
* * *In process of launching 6 key pharmaceuticals products since 2009* * *Executing therapeutic area strategy and advancing key compounds in pipeline* * *Leveraging global market strategies using local insights to successfully grow market share and expand geographic presence* * * -
Interleukin-6 Inhibitor Sirukumab (CNTO 136) Phase 2 Data Show Promise In The Treatment Of Active Rheumatoid Arthritis
Sirukumab Significantly Improved Signs and Symptoms of Rheumatoid Arthritis in Patients with Active Disease Despite Treatment with Methotrexate -
-
New Four Year STELARA™* Data Show Consistent Safety Profile Over Time In Patients With Moderate To Severe Plaque Psoriasis
Results Presented from the STELARA™ Clinical Development Program Also Demonstrate Consistency of Response across Multiple Ethnic Populations